News and Announcements
Folkestone Maxim A-Reit Securities Fund Reports Returns Of 4.1% In February 2017
- Published March 10, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
The reporting season saw the majority of A-REITs performing in line with or above market expectations. As anticipated the office A-REITs delivered a solid performance, with the Sydney office market, in particular, strong due to lack of new supply and low vacancy rates whilst the retail operating environment remains challenging.
KEY TAKEAWAYS:
- Guidance for FY2017 is on track, with upside for those A_REITs that are able to grow their funds management business or grow their portfolio through development of existing assets.
- The S&P/ASX 300 A-REIT Accumulation Index returned +4.1% in February outperforming the S&P/ASX 300 Accumulation Index, which returned +2.2%.
– However, the A-REITs are still down -0.9% on a YTD basis.
- At the end of February, the sector was trading at a 21.8% premium to NTA. The FY17 DPS yield of 5.0% represents a 229-basis point spread to 10-year bonds.
- The emerging theme in the A-REIT sector appears to be increased M&A activity. This is due to the relatively low cost of capital still on offer (both debt and equity) and the relative inability for A-REITs to acquire assets in the direct market.
Over the month, the Fund returned +4.14% (after fees, before tax) in line with the Benchmark return of +4.13%. Over the 12 month period ended 28 February, the Fund returned +12.64% (after fees, before tax), substantially outperforming the Benchmark return of +8.20% by +4.44%.
In February, positive contributions to results came from the Funds overweight exposure to Folkestone Education Trust (FET +12.4%), Rural Funds Group (RFF +4.1%) and Viva Energy REIT (VVR +6.7%).
Detracting from performance was the Fund’s zero exposures to Charter Hall Group (CHC +11.9%), Stockland Group (SGP +8.5%) and Vicinity Centres (VCX +1.0%).
At the end of February, the Fund’s investments comprised 16 ASX listed securities totalling 94.0% of the portfolio, 11 of which were constituents of the S&P/ASX 300 A-REIT Index, with the remaining 5 holdings being non-index stocks. A 0.1% exposure is held in an unlisted fund (a spin-off from the GPT), which the Fund expects to exit in due course. The balance of 5.9% of the portfolio was held in cash/liquid investments.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
